Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ultra-long-acting insulin: a new chapter in diabetes therapy?

The lancet. Diabetes & endocrinology·2024

Same author

Insulin icodec: evolution or revolution in diabetes therapy?

The lancet. Diabetes & endocrinology·2023

Same author

SGLT2 inhibitors in older adults: overcoming the age barrier.

The lancet. Healthy longevity·2023

Same author

Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?

The lancet. Diabetes & endocrinology·2020

Same author

Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments.

Drugs·2020

Same author

Evidence-based prescribing of diabetes medications: are we getting closer?

The lancet. Diabetes & endocrinology·2020

Search research articles

Related Experiment Video

Updated: May 10, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Complementing insulin therapy to achieve glycemic control.

Anthony H Barnett¹

¹Diabetes Centre, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK. Anthony.barnett@heartofengland.nhs.uk

Advances in Therapy

|June 26, 2013

Summary

Adding newer antidiabetes medications like GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors to insulin therapy can improve glycemic control in type 2 diabetes mellitus (T2DM) patients, while reducing weight gain and hypoglycemia risks.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Experiment Videos

Last Updated: May 10, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Area of Science:

Endocrinology
Pharmacology
Metabolic Diseases

Background:

Type 2 diabetes mellitus (T2DM) often requires escalating treatment complexity.
Insulin therapy is effective for hyperglycemia but carries risks of weight gain and hypoglycemia.
Combining insulin with other agents can enhance glycemic control and mitigate insulin-related adverse effects.

Purpose of the Study:

To review the benefits and drawbacks of various antidiabetes agents as add-on therapy to insulin in T2DM.
To focus on newer drug classes for patients with suboptimal glycemic control on insulin.

Main Methods:

Conducted a PubMed search (2003-2013) for clinical and review articles on insulin combination therapy in T2DM.
Included search terms for specific drug classes like DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors.
Analyzed study design, clinical relevance, and effects on insulin combination therapy.

Main Results:

Traditional agents (sulfonylureas, thiazolidinediones) can worsen weight gain and hypoglycemia risks.
Newer agents (GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors) improve glycemic control when added to insulin.
These newer agents have a low risk of hypoglycemia and promote weight reduction or neutrality.

Conclusions:

GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors are effective add-on therapies to insulin in T2DM.
These newer classes offer advantages over traditional agents due to lower risks of weight gain and hypoglycemia.
Consideration of these agents may lead to preferred insulin combination strategies.